Results 261 to 270 of about 1,949,289 (385)

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

open access: yesArthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Enhanced recovery after surgery compliance and outcomes in an international multisurgical cohort. [PDF]

open access: yesBJS Open
Nelson G   +9 more
europepmc   +1 more source

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting –Adjusted Comparison to a Historical Control Group Treated With Belimumab

open access: yesArthritis &Rheumatology, EarlyView.
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo   +15 more
wiley   +1 more source

An interpretative review of North American expert consensus on the clinical role of ex vivo lung perfusion (EVLP) with acellular perfusate. [PDF]

open access: yesJ Thorac Dis
Chen WY   +17 more
europepmc   +1 more source

Betamethasone Increases Pulmonary Compliance in Part by Surfactant-Independent Mechanisms in Preterm Rabbits

open access: yesPediatric Research, 1987
J. Fiascone   +4 more
semanticscholar   +1 more source

Drug‐Induced Raynaud's Phenomenon and Underlying Mechanism: A Disproportionality Analysis From the World Health Organization Pharmacovigilance Database

open access: yesArthritis &Rheumatology, EarlyView.
Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy